Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 28Multiple Myeloma 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hodgkin Disease 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Lymphoma, Non-Hodgkin 10Lymphoma 10Hematologic Neoplasms 10Neuroblastoma 9Myeloproliferative Disorders 9Anemia, Refractory, with Excess of Blasts 8Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Chronic 7Leukemia 7Neoplasms, Plasma Cell 6Lymphoma, T-Cell 6Leukemia, Biphenotypic, Acute 6Graft vs Host Disease 6Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Recurrence 4Primary Myelofibrosis 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Juvenile 4Hematologic Diseases 4Ganglioneuroblastoma 4Anemia, Aplastic 4

Interventions

Cyclophosphamide 4Prednisone 3Etoposide 3Doxorubicin 3etoposide phosphate 2Vincristine 2Brentuximab Vedotin 2tazemetostat 1prednylidene 1pembrolizumab 1fludarabine 1duvelisib 1deltacortene 1Prednisolone 1Melphalan 1Cytarabine 1Cholecalciferol 1Carmustine 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Melphalan × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡